AKT1 and neoplasm: The breakthrough lies in revealing the molecular mechanism by which artemisinin exerts anti-tumour effects through inhibiting the c-KIT/PI3K/AKT signalling pathway, which provides a theoretical basis for therapeutic efficacy.